Meeting
2018 ASCO Annual Meeting
Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
Authors
Nicolas Marcoux
Massachusetts General Hospital, Boston, MA
Nicolas Marcoux , Scott N. Gettinger , Grainne M. O'Kane , Kathryn Cecilia Arbour , Joel W. Neal , Hatim Husain , Tracey L. Evans , Julie R. Brahmer , Alona Muzikansky , Philip Bonomi , Salvatore A. Del Prete , Anna Wurtz , Anna F. Farago , Dora Dias-Santagata , Mari Mino-Kenudson , Helena Alexandra Yu , Heather A. Wakelee , Frances A. Shepherd , Zofia Piotrowska , Lecia V. Sequist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8573)
DOI
10.1200/JCO.2018.36.15_suppl.8573
Abstract #
8573
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.
First Author: Sai-Hong Ignatius Ou
Poster
2018 ASCO Annual Meeting
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
First Author: Pasi A. Janne
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu